Growth-Factor-Driven Rescue to Receptor Tyrosine Kinase (RTK) Inhibitors through Akt and Erk Phosphorylation in Pediatric Low Grade Astrocytoma and Ependymoma

Anti-angiogenic therapy in pediatric brain tumors: An effective strategy?

(2013) Mariska Sie et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

(2013) Seng Chuan Tang et al.   INTERNATIONAL JOURNAL OF CANCER

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

(2013) Yael P Mossé et al.   LANCET ONCOLOGY

Systematically Studying Kinase Inhibitor Induced Signaling Network Signatures by Integrating Both Therapeutic and Side Effects

(2013) Hongwei Shao et al.   PLoS One

Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment

(2012) Kosuke Akiyama et al.   AMERICAN JOURNAL OF PATHOLOGY

Pathological and Molecular Advances in Pediatric Low-Grade Astrocytoma

(2012) Fausto J. Rodriguez et al.   Annual Review of Pathology-Mechanisms of Disease

PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma

(2012) A. L. Ho et al.   CANCER RESEARCH

Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer

(2012) James S. Duncan et al.   CELL

Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib

(2012) Mukul Minocha et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma

(2012) Vipin Yadav et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02

(2012) E. Q. Lee et al.   NEURO-ONCOLOGY

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

(2012) Amy Young et al.   Cancer Discovery

Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin

(2011) Vijay Ramakrishnan et al.   AMERICAN JOURNAL OF HEMATOLOGY

The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo

(2011) Emelie A. Djerf Severinsson et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation

(2011) Bjoern Chapuy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice

(2011) Jan Gronych et al.   JOURNAL OF CLINICAL INVESTIGATION

Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells

(2011) Hiroaki Sugiyama et al.   JOURNAL OF GASTROENTEROLOGY

A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: A report from the Pediatric Brain Tumor Consortium

(2011) I. F. Pollack et al.   NEURO-ONCOLOGY

Vascular endothelial growth factor receptor 2 (VEGFR-2) signalling activity in paediatric pilocytic astrocytoma is restricted to tumour endothelial cells

(2011) A. H. Sikkema et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme

(2011) H J Jun et al.   ONCOGENE

Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme

(2010) John D. Hainsworth et al.   CANCER

A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas

(2010) J. Russell Geyer et al.   EUROPEAN JOURNAL OF CANCER

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

(2010) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors

(2010) B. Geoerger et al.   NEURO-ONCOLOGY

Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression

(2010) Kathryn E. Ware et al.   PLoS One

Kinome Profiling in Pediatric Brain Tumors as a New Approach for Target Discovery

(2009) A. H. Sikkema et al.   CANCER RESEARCH

The history of ependymoma management

(2009) Kyu-Won Shim et al.   CHILDS NERVOUS SYSTEM

Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma

(2009) A. Broniscer et al.   CLINICAL CANCER RESEARCH

Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment

(2009) J. S. Lagas et al.   CLINICAL CANCER RESEARCH

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

(2008) Regina I. Jakacki et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal growth factor administered in the periphery influences excitatory synaptic inputs onto midbrain dopaminergic neurons in postnatal mice

(2008) H. Namba et al.   NEUROSCIENCE